Biotech | January 04, 2022
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Bolstering neuroscience push with late-stage Tourette therapy
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
The approval marks a major milestone in the global fight against antimicrobial resistance
A one-shot gene-editing cholesterol therapy could soon be a reality
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
